



Why clear away one complication and create another?

Renagel News


Genzyme's Response to FDA Citizen's Petition – [Full response](#) | [Summary and background](#)

Genzyme Announces Positive Results from [DCOR Trial](#) Favoring Use of Renagel

Help your patients [access](#) Renagel now.

Renagel is indicated for the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis. Renagel controls phosphorus and Ca x P product without the concerns of calcium or metal accumulation. This website provides information regarding hyperphosphatemia and treatment with Renagel for Stage 5 Chronic Kidney Disease (CKD) patients.

Patients & Families >>



Health Care Professionals >>



Important Treatment Considerations

Renagel is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on hemodialysis · Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction · In a 52-week study, the most common side effects included vomiting, nausea, diarrhea, and dyspepsia · Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renagel. See [Renagel Full Prescribing Information](#).

Renagel[®] Tablets
sevelamer hydrochloride
800 mg tablets
Bind without buildup[™]

Search

Global Availability

This website is intended for use in the United States. Renagel is also available in these countries:

Contact Information

Genzyme Corporation

500 Kendall Street
Cambridge, MA 02142
T: 800 847 0069
F: 617 252 7600

[Email](#)

[Terms and Conditions of Use](#) | [Privacy Policy](#) | This site is intended for United States residents only.

© 2006 Genzyme Corporation. All rights reserved. Renagel and Genzyme are registered trademarks of Genzyme Corporation

